Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 2;11(6):1069-1073.
doi: 10.1021/acsmedchemlett.0c00075. eCollection 2020 Jun 11.

Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies

Vanna Sanna  1 , Mario Sechi  2
Affiliations

Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies

Vanna Sanna et al. ACS Med Chem Lett. .

Abstract

Engineered nanoparticles (NPs) to specifically deliver payload therapeutics to target cells involved in pathophysiological processes seem to offer a powerful strategy to overcome intrinsic limitations of drugs. In this Viewpoint we disclose the synergistic potential between medicinal chemistry and nanomedicine to exploit the "targeting concept" in developing effective nanotherapeutics, as well as the challenges and limitations that should be considered in pursuing their clinical translation, especially toward precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
(A) Passive drug targeting by enhanced permeation and retention (EPR) effect. (B) Active drug targeting.
Figure 2
Figure 2
Evolution of targeting therapies and nanomedicines and schematic representation of a targeted NP, i.e. BIND-014 (an example of Accurins). 3D model and image of NP created by Digizyme Inc.
Figure 3
Figure 3
Drug development process: interface between medicinal chemistry and nanotechnology.
Figure 4
Figure 4
Schematic of process for nanomaterial design and refinement based on the correlation between inherent properties of the tumor microenvironment (including EPR variability and nanobiointerface response) and disease specific biomarkers, throughout patient stratification toward precision medicine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Peer D.; Karo J. M.; Seungpyo H.; Farokhzad O. C.; Margalit S.; Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751–760. 10.1038/nnano.2007.387. - DOI - PubMed
    1. Kim B. Y.; Rutka J. T.; Chan W. C. Nanomedicine. N. Engl. J. Med. 2010, 363, 2434–2443. 10.1056/NEJMra0912273. - DOI - PubMed
    1. Min Y.; Caster J. M.; Eblan M. J.; Wang A. Z. Clinical Translation of Nanomedicine. Chem. Rev. 2015, 115, 11147–11190. 10.1021/acs.chemrev.5b00116. - DOI - PMC - PubMed
    1. Shi J.; Kantoff P. W.; Wooster R.; Farokhzad O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37. 10.1038/nrc.2016.108. - DOI - PMC - PubMed
    1. Srinivasarao M.; Galliford C. V.; Low P. S. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat. Rev. Drug Discovery 2015, 14, 203–219. 10.1038/nrd4519. - DOI - PubMed